| Filed On | Filing |
|---|---|
| 12 Nov 2026 | QUARTERLY REPORT |
| 03 Sep 2026 |
Form 4: Jolly Mohanjit, Director
Granted 120,000 Stock Option (right to buy) |
| 01 Sep 2026 |
Form 3: Leonard Jerry, Chief Financial Officer
No securities owned |
| 28 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Consulting Agreement (the “Agreement”) is made effective as of September 1, 2026 (the “Effective Date”), by and between Vyome Holdings, Inc., a Delaware corporation, with its principal place of business at Harvard Square, One Miffli... |
| 25 Aug 2026 |
8-K: Results of Operations and Financial Condition
Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet |
| 12 Aug 2026 | QUARTERLY REPORT |
| 29 May 2026 |
8-K: Results of Operations and Financial Condition
Vyome has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market1 |
| 12 May 2026 | QUARTERLY REPORT |
| 29 Apr 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “VYOME HOLDINGS, INC.”, FILED IN THIS OFFICE ON THE TWENTY-FOURTH DAY OF ... |
| 31 Mar 2026 |
Proxy statement: annual meeting on April 24, 2026
say-on-pay vote |
| 20 Mar 2026 | PRELIMINARY PROXY STATEMENT |
| 18 Mar 2026 | ANNUAL REPORT |
| 25 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Notes Purchase and Exchange Agreement (this “Agreement”) is entered into as of February 20, 2026 (the “Effective Date”) by and among (i) LiveChain, Inc., a Nevada corporation (“LICH”); (ii) LICH AI, Inc., a Delaware corporation and ... |
| 13 Feb 2026 |
8-K: Regulation FD Disclosure
VT - 1953 in Treating Symptoms of Malignant Fungating Wounds (MFW) PHASE 2 IST STUDY RESULTS & NEXT STEPS © Vyome Holdings, Inc. February 2026 |
| 28 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
1 U.S. Market & Product Assessment and Valuation of VT - 1953 for the Treatment of Symptoms of Malignant Fungating Wounds H1 2026 |
| 23 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
This letter of intent (this “LOI”) outlines the general terms and conditions of a prospective transaction (as further described herein, the “Transaction”) between LiveChain, Inc., a Delaware corporation (“LICH”), Remus Capital Series B I... |
| 26 Nov 2025 | PROSPECTUS |
| 19 Nov 2025 |
8-K: Results of Operations and Financial Condition
Completed a streamlined Nasdaq listing, with a 100% common stock capital structure |
| 19 Nov 2025 |
Form 4: Pomichter Stanley D Iii, Director
Granted 17,833 Stock Option (right to buy) |
| 19 Nov 2025 |
Form 3: Pomichter Stanley D Iii, Director
No securities owned |
Loading...